GPS Wealth Strategies Group’s Alexion Pharmaceuticals ALXN Stock Holding History

GPS Wealth Strategies Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-430	Closed	-$79K	–	1091
2021 Q2	$79K	Hold	430	–	–	0.02%	337
2021 Q1	$65K	Buy	+430	New	+$66.5K	0.02%	343

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

GPS Wealth Strategies Group's ALXN Position: Q3 2021 in Review

GPS Wealth Strategies Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 430 shares — an estimated $79K sold.

GPS Wealth Strategies Group first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $79K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

GPS Wealth Strategies Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
GPS Wealth Strategies Group sold 430 Alexion Pharmaceuticals shares in Q3 2021, an estimated $79K.
GPS Wealth Strategies Group first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
GPS Wealth Strategies Group's Alexion Pharmaceuticals position peaked at $79K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on GPS Wealth Strategies Group's 13F filing for Q3 2021, filed 20 Oct 2021.